US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Bulletin from an Extra Ordinary General meeting in Oncopeptides AB (publ)

Stockholm, Sweden – An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held on Friday, 23 September 2022. At the Extraordinary General Meeting, the following principal resolution was passed.· It was resolved, in accordance with the Board of Directors’ proposal, to authorize the Board of Directors to, until the next Annual General Meeting, on one or more occasions, decide upon issuances of new shares. New issues of shares may occur with or without preferential rights for shareholders of the company and may be made either in cash and/or by way of set-off or contribution in

Bulletin from the Annual General Meeting in Oncopeptides AB (publ)

Stockholm, Sweden – June 28, 2022 – The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Tuesday, 28 June 2022. At the Annual General Meeting, the following principal resolutions were passed.· The presented annual report was adopted, and the members of the Board of Directors and the CEOs were discharged from liability in respect of the financial year 2021. · It was resolved to carry forward the result for the year in accordance with the Board of Directors’ proposal. · The proposed remunerations to the Board of Directors, the Board of Directors’ committees and the

Bulletin from the Annual General Meeting in Oncopeptides AB (publ)

Stockholm, Sweden – The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Wednesday, 26 May 2021. At the Annual General Meeting, the following principal resolutions were passed.· The presented annual report was adopted and the members of the Board of Directors and the CEO were discharged from liability in respect of the financial year 2020. · It was resolved to carry forward the result for the year in accordance with the Board of Directors’ proposal. · The proposed remunerations to the Board of Directors, its committees and the Company’s auditor were approved. ·

Bulletin from the Annual General Meeting in Oncopeptides AB (publ)

Stockholm, Sweden – 26 May 2020 – Oncopeptides AB (publ)’s (ONCO) Annual General Meeting 2020 was held today, at Tändstickspalatset in Stockholm. At the Annual General Meeting, the following principal resolutions were passed.· The presented annual report was adopted and the members of the Board of Directors and the CEO were discharged from liability in respect of the financial year 2019. · It was resolved to carry forward the result for the year in accordance with the Board of Directors’ proposal. · The proposed remunerations to the Board of Directors, its committees and the Company’s

Bulletin from the Extraordinary General Meeting in Oncopeptides AB (publ)

Stockholm, Sweden – 17 December 2019 – An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held today, at Tändstickspalatset in Stockholm. At the Extraordinary General Meeting, the following principal resolutions were passed.· It was resolved, in accordance with the Board of Directors’ proposal, to issue not more than 2,200,000 warrants in order to ensure delivery of shares under the incentive program Co-worker LTIP 2019, adopted by the Annual General Meeting 2019. · It was resolved, in accordance with the Nomination Committee’s proposal, to issue not more than 23,491

BULLETIN FROM THE ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)

Stockholm, Sweden – 21 May 2019 – Oncopeptides AB (publ)’s (ONCO) Annual General Meeting 2019 was held today, at Tändstickspalatset in Stockholm. At the Annual General Meeting, the following principal resolutions were passed.·  The presented annual report was adopted and the members of the Board of Directors and the CEO were discharged from liability in respect of the financial year 2018. ·  It was resolved to carry forward the result for the year in accordance with the Board of Directors’ proposal. ·  The proposed remunerations to the Board of Directors, its committees and the

Bulletin from the Extraordinary General Meeting in Oncopeptides AB (PUBL)

Stockholm, Sweden –December 5, 2018 – An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held today, at Tändstickspalatset in Stockholm. At the Extraordinary General Meeting, the following principal resolutions were passed.·  The proposed remunerations to the new member of the Board of Directors were approved. ·  Jennifer Jackson was elected as new board member until the end of the annual general meeting 2019. It is noted that the Board of Directors also consists of Per Wold-Olsen (chairman), Brian Stuglik, Jonas Brambeck, Cecilia Daun Wennborg, Jarl Ulf Jungnelius,

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media